Jamjoom Pharmaceuticals Factory Company (TADAWUL: 4015)
Saudi Arabia
· Delayed Price · Currency is SAR 156.20
-1.20 (-0.76%)
Dec 19, 2024, 3:14 PM AST
Jamjoom Pharmaceuticals Factory Company Income Statement
Financials in millions SAR. Fiscal year is January - December.
Millions SAR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 |
| Revenue | 1,268 | 1,101 | 916.67 | 735.68 | 805.31 | 731.73 | Upgrade
|
| Revenue Growth (YoY) | 16.44% | 20.09% | 24.60% | -8.65% | 10.06% | 4.34% | Upgrade
|
| Cost of Revenue | 488.93 | 399.08 | 325.19 | 260.99 | 328.51 | 309.37 | Upgrade
|
| Gross Profit | 778.81 | 701.74 | 591.49 | 474.69 | 476.81 | 422.37 | Upgrade
|
| Selling, General & Admin | 370.67 | 350.38 | 314 | 251.89 | 236.89 | 247.83 | Upgrade
|
| Research & Development | 32.11 | 33.39 | 32.68 | 37 | - | - | Upgrade
|
| Operating Expenses | 407.55 | 385.86 | 349.03 | 288.89 | 236.89 | 247.83 | Upgrade
|
| Operating Income | 371.26 | 315.88 | 242.46 | 185.8 | 239.91 | 174.54 | Upgrade
|
| Interest Expense | -0.1 | -0.11 | -0.12 | - | - | - | Upgrade
|
| Interest & Investment Income | - | - | - | - | 1.5 | - | Upgrade
|
| Earnings From Equity Investments | 16.17 | 4.41 | -0.32 | -0.05 | -0.57 | - | Upgrade
|
| Currency Exchange Gain (Loss) | -16.06 | -1.33 | -47.95 | 2.01 | 4.11 | 3.21 | Upgrade
|
| Other Non Operating Income (Expenses) | -1.99 | -1.83 | -6.54 | 1.28 | -2.88 | -2.4 | Upgrade
|
| EBT Excluding Unusual Items | 369.28 | 317.02 | 187.53 | 189.04 | 242.08 | 175.35 | Upgrade
|
| Impairment of Goodwill | - | - | - | - | -2.11 | - | Upgrade
|
| Gain (Loss) on Sale of Investments | 3.28 | 0.04 | 0.01 | -1.04 | -8.32 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.04 | 0.04 | 0.03 | 0.09 | 0.09 | 0.32 | Upgrade
|
| Asset Writedown | -1.3 | -1.3 | -1.25 | - | - | - | Upgrade
|
| Pretax Income | 371.3 | 315.8 | 186.31 | 188.09 | 231.74 | 175.67 | Upgrade
|
| Income Tax Expense | 21.9 | 23.4 | 15 | 17.39 | 24.88 | 18.74 | Upgrade
|
| Earnings From Continuing Operations | 349.4 | 292.4 | 171.31 | 170.7 | 206.86 | 156.93 | Upgrade
|
| Net Income | 349.4 | 292.4 | 171.31 | 170.7 | 206.86 | 156.93 | Upgrade
|
| Net Income to Common | 349.4 | 292.4 | 171.31 | 170.7 | 206.86 | 156.93 | Upgrade
|
| Net Income Growth | 24.93% | 70.68% | 0.36% | -17.48% | 31.82% | 4.04% | Upgrade
|
| Shares Outstanding (Basic) | 70 | 70 | 70 | 10 | 10 | 10 | Upgrade
|
| Shares Outstanding (Diluted) | 70 | 70 | 70 | 10 | 10 | 10 | Upgrade
|
| Shares Change (YoY) | - | - | 600.00% | - | - | - | Upgrade
|
| EPS (Basic) | 4.99 | 4.18 | 2.45 | 17.07 | 20.69 | 15.69 | Upgrade
|
| EPS (Diluted) | 4.99 | 4.18 | 2.45 | 17.07 | 20.69 | 15.69 | Upgrade
|
| EPS Growth | 24.93% | 70.68% | -85.66% | -17.48% | 31.82% | 4.04% | Upgrade
|
| Free Cash Flow | 254.63 | 250.85 | 143.2 | 101.9 | 113.41 | 135.18 | Upgrade
|
| Free Cash Flow Per Share | 3.64 | 3.58 | 2.05 | 10.19 | 11.34 | 13.52 | Upgrade
|
| Dividend Per Share | 3.100 | 2.500 | - | - | - | - | Upgrade
|
| Gross Margin | 61.43% | 63.75% | 64.53% | 64.52% | 59.21% | 57.72% | Upgrade
|
| Operating Margin | 29.28% | 28.69% | 26.45% | 25.26% | 29.79% | 23.85% | Upgrade
|
| Profit Margin | 27.56% | 26.56% | 18.69% | 23.20% | 25.69% | 21.45% | Upgrade
|
| Free Cash Flow Margin | 20.09% | 22.79% | 15.62% | 13.85% | 14.08% | 18.47% | Upgrade
|
| EBITDA | 404.94 | 341.77 | 266.57 | 209.63 | 281.88 | 216.36 | Upgrade
|
| EBITDA Margin | 31.94% | 31.05% | 29.08% | 28.49% | 35.00% | 29.57% | Upgrade
|
| D&A For EBITDA | 33.68 | 25.89 | 24.12 | 23.82 | 41.96 | 41.82 | Upgrade
|
| EBIT | 371.26 | 315.88 | 242.46 | 185.8 | 239.91 | 174.54 | Upgrade
|
| EBIT Margin | 29.28% | 28.69% | 26.45% | 25.26% | 29.79% | 23.85% | Upgrade
|
| Effective Tax Rate | 5.90% | 7.41% | 8.05% | 9.25% | 10.74% | 10.67% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.